LIQUID BIOPSY MARKETS BY CANCER TYPE AND BY USAGE TYPE WITH IMPACT OF COVID-19 PANDEMIC. INCLUDING EXECUTIVE AND CONSULTANT GUIDES AND CUSTOMIZED FORECASTING AND ANALYSIS 2020-2024

$3,500.00

   385 Pages.  Our facts.  Your success.

Liquid Biopsy progress delayed by COVID pandemic but huge cancer screening opportunity still looms ...

The Screening, Diagnostic, Therapy Selection, Recurrence Monitoring and Screening Market Potential are all explored in this report. 

What is the impact of the COVID pandemic on the Liquid Biopsy market?  This report provides detailed analysis.

Circulating Tumor Cells?  Cell Free DNA?  Exosomes?  Find out about the technology in readily understood terms that explain the jargon.  Find the opportunities and the pitfalls.  Understand growth expectations and the ultimate potential market size.

A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA.  The technology has created the possibility of widespread SCREENING FOR ALL TYPES OF CANCERS WITH A BLOOD TEST.

GRAIL, a new company with impressive backing, has announced a single blood test to detect all cancers.  The company is now working on a 10,000-plus subject study, called the Circulating Cell-Free Genome Atlas (CCGA) to help identify cancer early.  The technology is moving faster than the market.  New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures.  The market is still in its infancy but has JUST MOVED OUT OF THE DEVELOPMENT PHASE AND INTO THE GROWTH PHASE.  The impact on the health care industry is enormous.  The report forecasts the market size out to 2024.  In addition, the report looks at potential market sizes by country, by cancer and by the four types of usage: screening, diagnosis, therapy selection and recurrence monitoring.

Use independent research that makes you the expert. Get our research team working for you by ordering this comprehensive report.  Your credit card order sends the report to your inbox instantly.  Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade to more information. Get an extra player on your team as unlimited assistance and breakout data is included with your purchase.

 

The report includes detailed breakouts for 15 Countries and 4 Regions along with breakouts for Lung, Breast, Colorectal, Prostate, Cervical, and Other Cancers as well as breakouts by Screening/Early Detection, Diagnostic, Therapy Monitoring and Recurrence Monitoring. 

 

See the Table of Contents.

Send an email to us at service@howesoundresearch.com and we will happily email you a FREE copy of SAMPLE PAGES FROM THIS REPORT without any obligation on your part.  And we will not pester you with phone calls!

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.  

 

 ABOUT THE LEAD AUTHOR

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. 

 

He is an experienced business and clinical professional.  He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping."  He has worked in laboratory testing and management for over 20 years.  Mr. Powell’s education includes:

B.Sc. (Chemistry) University of BC

M.B.A. (Finance and Policy) University of BC

Market Research  - Burke Institute

Finance for Senior Executives - Harvard Business School

Related products